Angiocrine Bioscience
Angiocrine Bioscience, Inc.
Angiocrine Bioscience is a clinical-stage biopharmaceutical company specializing in regenerative medicine. The company develops novel cellular therapies designed to repair and regenerate damaged tissues and organs by focusing on the underlying vascular system that supports them.
Products & Team
AB-205
AB-205 is the company's lead investigational cell therapy product, composed of allogeneic (donor-derived) E4ORF1+ human umbilical vein endothelial cells. Administered intravenously, it is being developed to treat severe toxicities in lymphoma patients undergoing high-dose chemotherapy and autologous stem cell transplantation.
AB-205 addresses the severe and often debilitating side effects of high-dose chemotherapy, such as damage to the oral and gastrointestinal tract, by repairing the vascular damage caused by the treatment, thereby improving patient outcomes and quality of life during cancer therapy.
Patients undergoing these intensive cancer treatments suffer from severe regimen-related toxicities, including painful and debilitating damage to the mucosal linings of the mouth and gastrointestinal tract, which can lead to treatment delays and increased morbidity.